ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Holland Recovering From Coronary Bypass; Henry Kaplan Receives Annual Prentis Award

July 25, 1980

Fondaparinux Prevents DVT In Acutely III Medical Patients

January 30, 2004

In Brief: Karen Antman And John Glick lead ASCO; ODAC to Meet June 7 On Tamoxifin Trial

May 27, 1994

Martha Fewell, Assistant To NCI Directors, To Retire

May 3, 2002

In Brief: Marks’ Appointment As President, Chief Executive Officer Of Memorial Sloan-Kettering, Official

June 27, 1980

ASCO, NCCS form cancer quality alliance.

November 11, 2005